title: Rapid screening and structural elucidation of a novel sibutramine analogue in a weight loss supplement: 11-desisobutyl-11-benzylsibutramine.
abstract: A novel analogue of sibutramine, 11-desisobutyl-11-benzylsibutramine, has been discovered. During routine ion mobility spectrometry (IMS) screening of a weight loss supplement collected at an US FDA import operation facility an unknown peak was observed. Further analysis of the supplement by liquid chromatography-mass spectrometry (LC-MS) and high resolution mass spectrometry revealed an unknown peak with a relative retention time of 1.04 with respect to sibutramine and a predicted formula of C20H24NCl. In order to elucidate the analogue's structure, it was isolated from the supplement and characterized by tandem mass spectrometry and nuclear magnetic resonance (NMR), which revealed the analogue possessed a benzyl moiety at the 11 position in place of the isobutyl group associated with sibutramine.
authors.affiliation: U.S. Food and Drug Administration, CDER Division of Pharmaceutical Analysis, 1114 Market St., St. Louis, MO 63101, USA. Daniel.Mans@fda.hhs.gov
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Mans
authors.forename: Ashley C
authors.initials: AC
authors.lastname: Gucinski
authors.forename: Jamie D
authors.initials: JD
authors.lastname: Dunn
authors.forename: Connie M
authors.initials: CM
authors.lastname: Gryniewicz-Ruzicka
authors.forename: Laura C
authors.initials: LC
authors.lastname: Mecker-Pogue
authors.forename: Jeff L-F
authors.initials: JL
authors.lastname: Kao
authors.forename: Xia
authors.initials: X
authors.lastname: Ge
mesh_terms: D002853:Chromatography, Liquid / Q000379:methods; D003503:Cyclobutanes / Q000737:chemistry*; D019587:Dietary Supplements; D009682:Magnetic Resonance Spectroscopy / Q000379:methods; D053719:Tandem Mass Spectrometry / Q000379:methods; D015431:Weight Loss / Q000187:drug effects*
chemical_list: D003503:Cyclobutanes; C587229:11-desisobutyl-11-benzylsibutramine; C058254:sibutramine